Your browser doesn't support javascript.
loading
Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States.
Schlienger, Raymond G; Korn, Jonathan R; Wehler, Elizabeth; Lopez Leon, Sandra; Yeaw, Jason.
Afiliação
  • Schlienger RG; Quantitative Safety and Epidemiology, Novartis Pharma AG, WSJ-027.3.021, Postfach, 4002, Basel, Switzerland. raymond.schlienger@novartis.com.
  • Korn JR; Health Economics and Outcomes Research, Quintiles IMS, One IMS Drive, Plymouth Meeting, PA, 19462, USA.
  • Wehler E; Health Economics and Outcomes Research, Quintiles IMS, One IMS Drive, Plymouth Meeting, PA, 19462, USA.
  • Lopez Leon S; Quantitative Safety and Epidemiology, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
  • Yeaw J; Health Economics and Outcomes Research, Quintiles IMS, 425 Market Street, San Francisco, CA, 94105, USA.
Am J Cardiovasc Drugs ; 17(6): 465-474, 2017 Dec.
Article em En | MEDLINE | ID: mdl-28779444
BACKGROUND: A non-interventional study suggested that use of angiotensin-converting enzyme inhibitors (ACEIs) or aliskiren was associated with an angioedema risk three times that of beta-blockers (BBs). OBJECTIVE: The aim was to assess angioedema incidence rates (IRs) and the relative angioedema risk of aliskiren compared to other antihypertensive drugs (AHDs). METHODS: A cohort study in hypertensive patients with an AHD prescription between 2007 and 2012 was conducted using data from the US PharMetrics Plus™ claims database. Angioedema was identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM) code 995.1. Additionally, a nested case-control analysis was conducted to assess the relative angioedema risk of aliskiren or other AHDs versus BBs. RESULTS: A total of 3,090,114 patients were included (aliskiren n = 30,720). There were 15,744 angioedema events (IR 2.28/1000 person-years; 95% confidence interval (CI) 2.24-2.32). Aliskiren IRs were: any aliskiren 2.58 (2.08-3.17), aliskiren monotherapy 1.71 (0.74-3.37), aliskiren fixed-dose combination (FDC) 1.27 (0.41-2.96), and aliskiren free-standing combination (FSC) 2.93 (2.31-3.66). The case-control analysis included 15,100 angioedema cases and 60,400 controls; the angioedema risk for both aliskiren monotherapy and FDC was not significantly different from BBs [adjusted odds ratio (adjOR) 0.99 (95% CI 0.45-2.20) and 1.06 (0.40-2.76)]; aliskiren FSC was associated with an increased angioedema risk [adjOR 3.29 (2.42-4.48)], mainly driven by concomitant ACEI use [adjOR 7.03 (4.10-12.05)]. CONCLUSIONS: The IR and risk of angioedema in patients with aliskiren monotherapy or FDC are comparable to BBs. The higher IR and risk of angioedema identified in the aliskiren FSC group may largely be driven by the concomitant use of ACEIs.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Fumaratos / Amidas / Angioedema / Anti-Hipertensivos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Fumaratos / Amidas / Angioedema / Anti-Hipertensivos Idioma: En Ano de publicação: 2017 Tipo de documento: Article